Frontiers in Clinical Drug Research - Alzheimer Disorders

Volume 3

by

Atta-ur-Rahman

DOI: 10.2174/97816810806801150301
eISBN: 978-1-68108-068-0, 2015
ISBN: 978-1-68108-069-7
ISSN: 2451-8743 (Print)
ISSN: 2214-5168 (Online)



Recommend this eBook to your Library



Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series concerned with Alzheimer's disease (AD)...[view complete introduction]

Table of Contents

Preface

- Pp. i-ii (2)

Atta-ur-Rahman

Download Free

List of Contributors

- Pp. iii-iv (2)

Atta-ur-Rahman

Download Free

Alpha and Theta Rhythms Activity is Associated to Morpho- Structural and Perfusional Modifications in Subjects with Prodromal Alzheimer`s Disease

- Pp. 3-19 (17)

Vito Davide Moretti, Prestia A, Binetti G, Zanetti O and Frisoni G B

View Abstract Purchase Chapter

New Aspects of Therapeutic Management in Alzheimer`s Disease

- Pp. 20-114 (95)

Cristian Dinu Popescu, Dan Trofin, Daniela Trofin, Bogdan Ignat and Daniela Matei

View Abstract Purchase Chapter

Evidence-Based Treatment and Prevention of Behavioural and Psychological Symptoms of Alzheimer`s Disease

- Pp. 115-134 (20)

Anne Corbett and Clive Ballard

View Abstract Purchase Chapter

BACE Inhibition as a Therapeutic Strategy for Alzheimer`s Disease

- Pp. 135-230 (96)

Genevieve Evin, Stephanie J. Fuller and Jenny M. Gunnersen

View Abstract Download Free

The Development of Drug Therapies for Frontotemporal Dementia Caused by <i>Progranulin</i> Mutations

- Pp. 231-291 (61)

Louis De Muynck and Philip Van Damme

View Abstract Download Free

Subject Index

- Pp. 292-297 (6)

Atta-ur-Rahman

Download Free

Preface

Alzheimer’s disease (AD) is the most common age-related multifactorial neurodegenerative disease, which is described as the failure of cognitive performance and behavioral capabilities. With the progression and development of this disease, neurodegeneration in the brain can finally lead to dementia.

Many researchers are striving to understand, slow down the onset and eventually cure AD. The present 3rd volume of Frontiers in Clinical Drug Research – Alzheimer Disorders, presents some of the most recent and remarkable advances in the field, in the form of cutting edge reviews written by eminent experts. It is a compilation of five well written chapters that include advances in therapeutic management, new strategies and evidence-based treatment and prevention Alzheimer’s disease.

Biomarkers have served an important role for the diagnosis and for monitoring the progression of Alzheimer’s disease (AD). Moretti et al. in Chapter 1 describe a study involving the association between alpha3/alpha2 frequency power ratio with rCBF changes in subjects with mild cognitive impairment (MCI). The association and a complex interplay of alpha and theta rhythms activity with morpho-structural and perfusional modifications in subjects with prodromal Alzheimer's disease is also discussed.

Alzheimer’s disease affects both patients and their families. Popescu et al. in Chapter 2 discuss the new symptomatic and disease modifying therapies including changes in life style. Many of these therapeutic approaches are directed towards modifying the amyloid cascade, while others aim at tau pathology, inflammation, oxidative stress and neurogenesis The authors also discuss how better management of cardiovascular risk factors, and involvement in social and professional activities can assist in the reduction in the occurrence of Alzheimer’s disease.

Behavioural and psychological symptoms of dementia (BPSD) include agitation and aggressive behaviour. Corbett and Ballard in Chapter 3 highlight the reasons and impacts of BPSD in patients with Alzheimer’s disease. The review provides evidences for the role of both pharmacological and non-pharmacological treatments in the prevention and treatment of BPSD.

The characteristic hallmark of AD is the presence of amyloid plaques in the brain containing aggregates of the neurotoxic amyloid-β peptide Aβ. The BACE1 inhibitor serves as a key drug target in AD. Evin et al. in Chapter 4 comprehensively explain the promises and the possible drawbacks of BACE inhibition strategy and draw attention to the development of BACE inhibitors for AD therapy.

Frontotemporal dementia (FTD) is a collection of disorders caused by progressive cell degeneration in the brain's frontal or temporal lobes. The development of drug therapies for frontotemporal dementia caused by progranulin mutations is extensively reviewed in Chapter 5 by De Muynck and Van Damme. Due to the neurotrophic and anti-inflammatory properties of progranulin, it has shown neuroprotective effects in models of Parkinson’s disease and Alzheimer’s disease. As progranulin has neurotrophic and anti-inflammatory properties, therapeutic interventions that can augment progranulin levels may prove to be useful in other forms of neurodegeneration

This 3rd volume of the book series represents the results of a significant amount of work by many eminent researchers to whom I am grateful. I would also like to express my gratitude to the excellent team of Bentham Science Publishers, especially Ms. Fariya Zulfiqar (Assistant Manager Publication), Mr. Shehzad Naqvi (Senior Manager Publication), led by Mr. Mahmood Alam, (Director Publication), who deserve our appreciation.

Atta-ur-Rahman
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

Editor(s):
Atta-ur-Rahman FRS
Kings College, University of Cambridge
Honorary Life Fellow
Cambridge
UK




Contributor(s):
Anne Corbett
Wolfson Centre for Age Related Diseases, Guy’s Campus
King’s College London
London
SE1 1UL
UK


Binetti G
IRCCS S. Giovanni di Dio Fatebenefratelli
Brescia
Italy


Bogdan Ignat
Faculty of General Medicine, Department of Neurology
University of Medicine and Pharmacy “Grigore T. Popa” Iasi
Romania


Clive Ballard
Wolfson Centre for Age Related Diseases, Guy’s Campus
King’s College London
London
SE1 1UL
UK


Cristian Dinu Popescu
Faculty of General Medicine, Department of Neurology
University of Medicine and Pharmacy “Grigore T. Popa” Iasi
Romania


Dan Trofin
Faculty of General Medicine, Department of Neurology
University of Medicine and Pharmacy “Grigore T. Popa” Iasi
Romania


Daniela Matei
Faculty of Biomedical Engineering, Biomedical Sciences
University of Medicine and Pharmacy “Grigore T. Popa” Iasi
Romania


Daniela Trofin
Faculty of Biomedical Engineering, Biomedical Sciences
University of Medicine and Pharmacy “Grigore T. Popa” Iasi
Romania


Frisoni G B
IRCCS S. Giovanni di Dio Fatebenefratelli
Brescia
Italy


Genevieve Evin
Florey Institute of Neuroscience and Mental Health, and Department of Anatomy and Neuroscience
The University of Melbourne
Parkville
Victoria
Australia


Jenny M. Gunnersen
Florey Institute of Neuroscience and Mental Health, and Department of Anatomy and Neuroscience
The University of Melbourne
Parkville
Victoria
Australia


Louis De Muynck
Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND)
Leuven
Belgium
/
VIB,Vesalius Research Center
Leuven
Belgium


Philip Van Damme
Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND)
Leuven
Belgium
/
VIB, Vesalius Research Center
Leuven
Belgium


Prestia A
IRCCS S. Giovanni di Dio Fatebenefratelli
Brescia
Italy


Stephanie J. Fuller
Florey Institute of Neuroscience and Mental Health, and Department of Anatomy and Neuroscience
The University of Melbourne
Parkville
Victoria
Australia


Vito Davide Moretti
IRCCS S. Giovanni di Dio Fatebenefratelli
Brescia
Italy


Zanetti O
IRCCS S. Giovanni di Dio Fatebenefratelli
Brescia
Italy




Advertisement


Related Journals



Related Books



Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science